Evidence map›Paper›PMID 42309537›Full record

ArticleBritish journal of haematology2026

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.

Rodothea Amerikanou, Talha Munir, Kristian Bowles, Christopher McNamara, Nikesh Chavda, Elizabeth Price, Jagdish Adiyodi, Alasdair Coles, Philippa Kelsey, Jeffery Smith and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rodothea AmerikanouUniversity College London Hospitals NHS Foundation Trust, London, UK.
Talha MunirLeeds Teaching Hospitals, Leeds, UK.ORCID https://orcid.org/0000-0002-2901-0769
Kristian BowlesNorwich Medical School, University of East Anglia, Norwich, UK.
Christopher McNamaraUniversity College London Hospitals NHS Foundation Trust, London, UK.
Nikesh ChavdaUniversity Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Elizabeth PriceGreat Western Hospitals NHS Foundation Trust, Swindon, UK.
Jagdish AdiyodiRoyal Blackburn Teaching Hospital, Blackburn, UK.
Alasdair ColesCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Philippa KelseySheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Jeffery SmithThe Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.ORCID https://orcid.org/0000-0001-9613-8976
Richard AdamsUniversity Hospital of Wales, Cardiff, UK.
Hayder HusseinQueen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.ORCID https://orcid.org/0000-0002-9502-2952
Rui ZhaoTorbay Hospital, Torbay and South Devon NHS Foundation Trust, Torbay, UK.ORCID https://orcid.org/0000-0001-5208-1672
Trung NguyenGreat Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Matthew CollinNewcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, UK.ORCID https://orcid.org/0000-0001-6585-9586
Satyen GohilUniversity College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-0484-991X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trametinib (MEK inhibitor) shows efficacy in refractory and high-risk adult histiocytic neoplasms. At a median follow-up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).

Indexed as

Antineoplastic AgentsHistiocytic Disorders, MalignantProtein Kinase InhibitorsPyridonesPyrimidinonesAdultAgedFemaleHumansMaleMiddle AgedTreatment OutcomeUnited KingdomAntineoplastic AgentsProtein Kinase InhibitorsPyridonesPyrimidinonestrametinibErdheim–Chester diseasehistiocytic sarcomaLangerhans cell histiocytosisRosai–Dorfman disease

Identifiers

PMID42309537
PMCPMC13462067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.